investors & media
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Biologics License Application (BLA) for lovo-cel for sickle cell disease submitted to FDA - - First commercial infusions completed for both ZYNTEGLO ® and SKYSONA ® - - Ended quarter with $ 364M in cash, cash equivalents, marketable securities and restricted cash – SOMERVILLE, Mass.Read more
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 27, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company’s first quarter financial results, including commercial, regulatory and operational updates, will be released pre-market on Tuesday, May 9 .Read more
BLA submission based on data from the largest and most mature clinical development program for any gene therapy in sickle cell disease SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) toRead more